874 participants
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-07-22
- Start Date:
- 2021-10-04
- Completion:
- 2024-06-24
Conditions
- Breast Neoplasms
- Neoplasm Metastasis
Interventions
- DRUG